(688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Proposed Deregistration of Wholly-owned Subsidiary
Filed with SSE · Stock code 688488 · · 2 pages · Chinese
Summary by 6ix AI
Jiangsu Aidea Pharmaceutical Group Co., Ltd. announced plans to deregister its wholly-owned subsidiary, Nanjing Ansailai Pharmaceutical Technology Co., Ltd.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Jiangsu Aidea Pharmaceutical Group Co., Ltd. on 6ix
Story so far
- (688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for ADC118 Tablets
- Announcement on Signing the Supplementary Agreement to Conditional Stock Subscription Contract with a Specific Investor and Related Party Transaction
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
Earlier from Jiangsu Aidea Pharmaceutical
- (688488)"JIANGSU AIDEA PHARMACEUTICAL GROUP CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for ADC118 Tablets
- Announcement on Signing the Supplementary Agreement to Conditional Stock Subscription Contract with a Specific Investor and Related Party Transaction
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Announcement on Failure to Satisfy Exercise Conditions for the 1st Exercise Period under the 2025 Stock Option Incentive Plan and Cancellation of Certain Stock Options
- Announcement on Pledge of Certain Shares Held by Persons Acting in Concert with the Actual Controller
Follow Jiangsu Aidea Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Aidea Pharmaceutical